脐血CIK细胞抗肿瘤研究及临床应用进展

肿瘤的生物治疗尤其是用免疫活性细胞输注的过继免疫治疗是目前研究热点之一，是继手术、放疗、化疗三大常规治疗的又一新的治疗肿瘤的方法。此疗法不仅是常规抗肿瘤治疗的补充，更是为晚期不宜手术或无法承受放疗化疗所带来的副作用的患者开辟了一个新的治疗途径，可取得常规方法无法达到的疗效，成为人类抗击肿瘤最有希望的战略措施之一。细胞因子诱导的杀伤细胞是用于肿瘤过继免疫治疗较为有效的免疫效应细胞之一，是目前所知杀伤活性最高的肿瘤杀伤细胞，具有增殖速度快、杀瘤活性高、杀瘤谱广的特点，对正常骨髓造血前体毒性小，已大量应用于临床。脐血CIK细胞增殖速度、杀瘤活性优于外周血CIK细胞，移植后移植物抗宿主病发生率更低等优点，因而受到广泛关注。本文就脐血CIK细胞的抗肿瘤研究的特点及，临床应用进展作一综述。

Antitumor Research and Clinical Application of Cord Blood CIK Cells

Adoptive immunothcrapy is one of the hottest subject in biotherapy of tumor, which has been a new tumor therapy method followed by surgery, radiotherapy, and chemotherapy three conventional treatment.This treatment is not only the supplement to conventional therapy, but also apply hope to people who can not sustain the side effects of radiotherapy and chemotherapy any longer. Cytokineqnduced killer （C1K） is a new generation of adoptive immunocell therapy. CIK cells is known as the highest efficient tumor-killing cell, not only have the characteristics of rapid proliferation, high efficiency, and broad spectrum in killing of tumor cells, but also have small toxicity to hematopoietic progenitor cells of normal marrow. It has been widely used in clinical. The cells proliferation speed, the anti-tumor activity and the incidence of graft-versus-host disease （GVHD） of CIK cells originated from umbilical cord blood are superior to those from peripheral blood. So, it has attracted the worldwide extensive attention. This article reviewed the anti-tumor research progress and clinical application of Cord Blood CIK cells.